Medical Journey of Patients with Mild Cognitive Impairment and Mild Alzheimer’s Disease Dementia: A Cross-sectional Survey of Patients, Care Partners, and Neurologists

Alzheimer’s disease (AD) is a progressive, neurodegenerative disease presenting along a continuum ranging from asymptomatic disease to mild cognitive impairment (MCI), followed by dementia characterized as mild, moderate, or severe. To better understand the medical journey of patients with all-cause MCI or mild AD dementia from the perspective of patients, care partners, and physicians. Cross-sectional study. Online surveys in the United States between February 4, 2021, and March 1, 2021. 103 patients with all-cause MCI or mild AD dementia and 150 care partners participated in this survey. 301 physicians (75 of whom were neurologists) completed a survey. The surveys included questions regarding attitudes, experiences, and behaviors related to diagnosis and management of MCI and mild AD dementia. For the patient and care partner surveys, questions regarding healthcare received for MCI and mild AD dementia were only asked of care partners. Most patients (73%) had a similar medical journey. The majority (64%) initially consulted a primary care physician on average 15 months after symptom onset, with symptoms primarily consisting of forgetfulness and short-term memory loss. About half (51%) of patients in the typical medical journey were diagnosed by a neurologist. Upon diagnosis, most neurologists reported having discussions with patients and care partners about the potential causes of MCI or mild AD dementia (83%); of these physicians, 83% explained the effect other conditions have on the risk of the diagnoses and symptom progression. Neurologists (52%) consider themselves the coordinator of care for patients with MCI or mild AD dementia. Amongst patients and care partners, about one-third (35%) perceive the neurologists to be the coordinating physician. Neurologists commonly diagnose MCI and mild AD dementia but are typically not the first point of contact in the medical journey, and patients do not consult with a physician for over a year after symptom onset. Neurologists play a key role in the medical journey for patients and care partners, and could help ensure earlier diagnosis and treatment, and improve clinical outcomes by coordinating MCI and mild AD dementia care and collaborating with primary care physicians.

[1]  Anonymous,et al.  2022 Alzheimer's disease facts and figures , 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[2]  Sonia Santander Ballestín,et al.  Vitamin Supplementation and Dementia: A Systematic Review , 2022, Nutrients.

[3]  Tih-Shih Lee,et al.  Cardiometabolic and Vascular Disease Factors and Mild Cognitive Impairment and Dementia , 2022, Gerontology.

[4]  Mina Esmail Zadeh Nojoo Kambar,et al.  Alzheimer's disease drug development pipeline: 2022 , 2022, Alzheimer's & dementia.

[5]  Nannan Shi,et al.  Diagnosis and Treatment for Mild Cognitive Impairment: A Systematic Review of Clinical Practice Guidelines and Consensus Statements , 2021, Frontiers in Neurology.

[6]  J. Weuve,et al.  Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020–2060) , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[7]  M. Sabbagh,et al.  Diagnosis of Early Alzheimer’s Disease: Clinical Practice in 2021 , 2021, The Journal of Prevention of Alzheimer's Disease.

[8]  M. Sabbagh,et al.  Early Stages of Alzheimer's Disease: Evolving the Care Team for Optimal Patient Management , 2021, Frontiers in Neurology.

[9]  Jorge Riquelme-Galindo,et al.  Experience of People in Mild and Moderate Stages of Alzheimer’s Disease in Spain , 2020, Aquichan.

[10]  J. Cummings,et al.  Repurposed agents in the Alzheimer’s disease drug development pipeline , 2020, Alzheimer's Research & Therapy.

[11]  J. Lingler,et al.  Patients’ and Family Members’ Subjective Experiences of a Diagnostic Evaluation of Mild Cognitive Impairment , 2018, Journal of patient experience.

[12]  R. Khandker,et al.  Physician Perceptions about the Barriers to Prompt Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease , 2019, International journal of Alzheimer's disease.

[13]  M. Carrillo,et al.  Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia , 2019, JAMA.

[14]  A. Atri The Alzheimer's Disease Clinical Spectrum: Diagnosis and Management. , 2019, The Medical clinics of North America.

[15]  P. Sachdev,et al.  Midlife Hypertension and Alzheimer's Disease: A Systematic Review and Meta-Analysis. , 2019, Journal of Alzheimer's disease : JAD.

[16]  Carme Carrion,et al.  Cognitive Therapy for Dementia Patients: A Systematic Review , 2018, Dementia and Geriatric Cognitive Disorders.

[17]  C. Jack,et al.  NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[18]  Ron Brookmeyer,et al.  Forecasting the prevalence of preclinical and clinical Alzheimer's disease in the United States , 2018, Alzheimer's & Dementia.

[19]  Ronald C. Petersen,et al.  Practice guideline update summary: Mild cognitive impairment , 2018, Neurology.

[20]  J. Karlawish,et al.  Awareness of Mild Cognitive Impairment and Mild Alzheimer’s Disease Dementia Diagnoses Associated With Lower Self-Ratings of Quality of Life in Older Adults , 2017, The journals of gerontology. Series B, Psychological sciences and social sciences.

[21]  R. Kane,et al.  Societal and Family Lifetime Cost of Dementia: Implications for Policy , 2017, Journal of the American Geriatrics Society.

[22]  Amit J. Shah,et al.  Correlates of Dementia and Mild Cognitive Impairment in Patients With Atrial Fibrillation: The Atherosclerosis Risk in Communities Neurocognitive Study (ARIC‐NCS) , 2017, Journal of the American Heart Association.

[23]  J. Karlawish,et al.  A Typical Day With Mild Cognitive Impairment. , 2017, American journal of public health.

[24]  U. Sambamoorthi,et al.  Direct and indirect cost of managing alzheimer’s disease and related dementias in the United States , 2017, Expert review of pharmacoeconomics & outcomes research.

[25]  Sterling C. Johnson,et al.  Insulin resistance predicts brain amyloid deposition in late middle-aged adults , 2015, Alzheimer's & Dementia.

[26]  F. Jessen,et al.  Elevated HbA1c is associated with increased risk of incident dementia in primary care patients. , 2015, Journal of Alzheimer's disease : JAD.

[27]  Z. Khachaturian,et al.  Alzheimer's & Dementia: Translational Research & Clinical Interventions , 2015 .

[28]  M. Vinciguerra,et al.  An association study between epicardial fat thickness and cognitive impairment in the elderly. , 2014, American journal of physiology. Heart and circulatory physiology.

[29]  R. Beard,et al.  Making sense of nonsense: experiences of mild cognitive impairment. , 2013, Sociology of health & illness.

[30]  G. Eslick,et al.  Type 2 diabetes as a risk factor for Alzheimer's disease: the confounders, interactions, and neuropathology associated with this relationship. , 2013, Epidemiologic reviews.

[31]  Paco Martorell,et al.  Monetary costs of dementia in the United States. , 2013, The New England journal of medicine.

[32]  Amy E. Sanders,et al.  Age-specific and Sex-specific Prevalence and Incidence of Mild Cognitive Impairment, Dementia, and Alzheimer Dementia in Blacks and Whites: A Report From the Einstein Aging Study , 2012, Alzheimer disease and associated disorders.

[33]  E. Sinforiani,et al.  Caregiver Burden and Coping in Early-stage Alzheimer Disease , 2012, Alzheimer disease and associated disorders.

[34]  N. Meader,et al.  Clinical recognition of dementia and cognitive impairment in primary care: a meta‐analysis of physician accuracy , 2011, Acta psychiatrica Scandinavica.

[35]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[36]  Nick C Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[37]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[38]  M. Albert,et al.  Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[39]  N. Bhat Linking cardiometabolic disorders to sporadic Alzheimer’s disease: a perspective on potential mechanisms and mediators , 2010, Journal of neurochemistry.

[40]  M. Dale,et al.  Review: Obesity and Alzheimer’s Disease: A Link Between Body Weight and Cognitive Function in Old Age , 2009, American journal of Alzheimer's disease and other dementias.

[41]  Z. Khachaturian Alzheimer's & Dementia: The Journal of the Alzheimer's Association , 2008, Alzheimer's & Dementia.

[42]  Richard Schulz,et al.  Making sense of mild cognitive impairment: a qualitative exploration of the patient's experience. , 2006, The Gerontologist.

[43]  A. Ott Risk of dementia: The Rotterdam Study , 1997 .

[44]  Vijaya L. Melnick,et al.  Alzheimer’s Dementia , 1985, Contemporary Issues in Biomedicine, Ethics, and Society.

[45]  M. Ganguli,et al.  Practice guideline update summary: Mild cognitive impairment Report of theGuidelineDevelopment, Dissemination, and Implementation Subcommittee of the American Academy ofNeurology , 2022 .